Moneycontrol
Get App
SENSEX NIFTY
you are here:

Aurobindo Pharma Ltd.

BSE: 524804 | NSE: AUROPHARMA |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE406A01037 | SECTOR: Pharmaceuticals

Success
Alert
Please select a Day.
Info

BSE Live

Jan 17, 16:00
486.25 10.10 (2.12%)
Volume
AVERAGE VOLUME
5-Day
98,023
10-Day
90,754
30-Day
95,930
90,692
  • Prev. Close

    476.15

  • Open Price

    476.30

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Jan 17, 15:59
485.95 10.10 (2.12%)
Volume
AVERAGE VOLUME
5-Day
2,728,268
10-Day
2,331,297
30-Day
2,519,707
2,644,076
  • Prev. Close

    475.85

  • Open Price

    477.40

  • Bid Price (Qty.)

    485.95 (53)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Aurobindo Pharm

  • Jan 18, 2020 11:57 Source: BSE

    Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herewith enclose notice issued for the attention of equity shareholders of the Company on 13.01.2020 which was published on 18.01.2020, intimating that the equity shares in respect of which dividend remain unclaimed for seven consecutive years, would be transferred to Investor Education and Protection Fund (IEPF), in the following newspapers. Business Standard (English daily) Andhra Prabha (Telugu daily). Kindly take the above information on record.

  • Jan 17, 2020 15:28 Source: BSE

    Aurobindo Pharma - Contact Details Of Registrar And Share Transfer Agent (RTA)

    Please find attached the revised contact details of the Company''s Registrar and Share Transfer Agents (RTA), M/s Kfin Technologies Private Limited. We request you to update the above revised contact details of RTA on your records.

  • Jan 14, 2020 12:34 Source: NSE

    Aurobindo Pharma Limited

    Aurobindo Pharma Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

  • Jan 14, 2020 12:14 Source: BSE

    Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    We would like to inform you that we are participating in the 38th Annual JP Morgan Healthcare Conference being held in San Francisco, California, USA on 14th January, 2020 (US timings). The attached presentation will be used in the aforesaid investor conference. The presentation is also being uploaded on the website of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

  • Jan 13, 2020 10:23 Source: BSE

    Aurobindo Pharma - Statement Of Investor Complaints For The Quarter Ended December 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    0770
    Name of the Signatory :- B Adireddy
    Designation :- Company Secretary and Compliance Officer

  • Jan 10, 2020 17:03 Source: NSE

    Aurobindo Pharma Limited

    Aurobindo Pharma Limited has informed the Exchange regarding ''In compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby certify that the securities received for the period from October 1, 2019 to December 31, 2019 for dematerialization have been mutilated and cancelled after due verification. The name of the respective depository has been substituted as the registered owner in respect of those dematerialized equity shares, in our records within 15 days of receipt of certificate of securities. Further, the certificates of securities which were dematerialized, are listed on the Stock Exchanges, where earlier issued securities of the Company were listed. ''.

  • Jan 10, 2020 16:07 Source: BSE

    Aurobindo Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    In compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby certify that the securities received for the period from October 1, 2019 to December 31, 2019 for dematerialization have been mutilated and cancelled after due verification. The name of the respective depository has been substituted as the registered owner in respect of those dematerialized equity shares, in our records within 15 days of receipt of certificate of securities. Further, the certificates of securities which were dematerialized, are listed on the Stock Exchanges, where earlier issued securities of the Company were listed.

  • Jan 10, 2020 15:33 Source: BSE

    Aurobindo Pharma - Shareholding for the Period Ended December 31, 2019

    Aurobindo Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

  • Dec 31, 2019 10:35 Source: NSE

    Aurobindo Pharma Limited

    Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

  • Dec 31, 2019 10:06 Source: BSE

    Aurobindo Pharma - Closure of Trading Window

    This is to inform that as per the Company''s Internal Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons, the Trading Window for dealing in the securities of the Company would remain closed for all designated persons including promoters, directors, key managerial personnel, employees, connected persons and their immediate relatives with effect from January 1, 2020 till 48 hours after the declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ending on December 31, 2019. The date of Board Meeting for declaration of the financial results of the Company for the third quarter and nine months period ending on December 31, 2019 will be intimated in due course.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Nov 12, 2019
Remark : Quarterly Results & Interim Dividend